Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Sarcoma 1Genitourinary 1

Conditions

Wilms Tumor 1Sarcoma 1Neuroblastoma 1Neoplasms 1

Interventions

Filgrastim 9Cyclophosphamide 9X-Rays 7Phantoms, Imaging 7Specimen Handling 6Magnetic Resonance Spectroscopy 6Flow Cytometry 6Carboplatin 6Temozolomide 5Nuclear Medicine Department, Hospital 5Melphalan 5Granulocyte Colony-Stimulating Factor 5Busulfan 5Biopsy 5Therapeutics 4Polymerase Chain Reaction 4Peripheral Blood Stem Cell Transplantation 4Etoposide 4Amplified Fragment Length Polymorphism Analysis 4fludarabine 3Vincristine 3Topotecan 3Thiotepa 3Stem Cell Transplantation 3Psychiatric Rehabilitation 3Methylprednisolone 3Itraconazole 3Irinotecan 3Ipilimumab 3Immunologic Techniques 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × Hematopoietic Stem Cell Transplantation × Genitourinary × Clear all
NCT00405327 2017-11-06

A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation

University of Michigan Rogel Cancer Center

Phase 2 Completed
16 enrolled
CNSGenitourinarySarcoma

Neoplasms, Wilms Tumor, Neuroblastoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡